Daiichi Sankyo, AstraZeneca team with Summit Therapeutics on cancer drug trials
SMMT•Daiichi Sankyo, AstraZeneca and Summit Therapeutics entered a clinical trial collaboration in October 2026 to evaluate Datroway with ivonescimab across multiple tumor types. They plan to begin with a Phase 3 trial in first-line treatment of triple-negative breast cancer.
1. Trial collaboration
Daiichi Sankyo and AstraZeneca entered a clinical trial collaboration with Summit Therapeutics in October 2026. The partners will evaluate Datroway combined with ivonescimab across multiple tumor types, including lung and breast cancers, beginning with a planned Phase 3 trial in first-line treatment of triple-negative breast cancer.
